It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green whileBSX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 3 TA indicator(s) are bullish while BSX’s TA Score has 6 bullish TA indicator(s).
BDX (@Pharmaceuticals: Other) experienced а -2.25% price change this week, while BSX (@Medical/Nursing Services) price change was -8.43% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.23%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +7.18%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +3.66%. For the same industry, the average monthly price growth was +5.73%, and the average quarterly price growth was +6.96%.
BDX is expected to report earnings on Nov 06, 2025.
BSX is expected to report earnings on Oct 22, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+3.66% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
BDX | BSX | BDX / BSX | |
Capitalization | 53.2B | 148B | 36% |
EBITDA | 4.92B | 4.65B | 106% |
Gain YTD | -16.600 | 10.815 | -153% |
P/E Ratio | 34.04 | 58.92 | 58% |
Revenue | 21.4B | 18.5B | 116% |
Total Cash | N/A | 534M | - |
Total Debt | 19.3B | 12B | 161% |
BDX | BSX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 6 | |
SMR RATING 1..100 | 82 | 64 | |
PRICE GROWTH RATING 1..100 | 62 | 57 | |
P/E GROWTH RATING 1..100 | 82 | 65 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (20) in the Medical Specialties industry is somewhat better than the same rating for BSX (82). This means that BDX’s stock grew somewhat faster than BSX’s over the last 12 months.
BSX's Profit vs Risk Rating (6) in the Medical Specialties industry is significantly better than the same rating for BDX (100). This means that BSX’s stock grew significantly faster than BDX’s over the last 12 months.
BSX's SMR Rating (64) in the Medical Specialties industry is in the same range as BDX (82). This means that BSX’s stock grew similarly to BDX’s over the last 12 months.
BSX's Price Growth Rating (57) in the Medical Specialties industry is in the same range as BDX (62). This means that BSX’s stock grew similarly to BDX’s over the last 12 months.
BSX's P/E Growth Rating (65) in the Medical Specialties industry is in the same range as BDX (82). This means that BSX’s stock grew similarly to BDX’s over the last 12 months.
BDX | BSX | |
---|---|---|
RSI ODDS (%) | 2 days ago58% | 2 days ago90% |
Stochastic ODDS (%) | 2 days ago50% | 2 days ago75% |
Momentum ODDS (%) | 2 days ago46% | 2 days ago48% |
MACD ODDS (%) | 2 days ago48% | 2 days ago47% |
TrendWeek ODDS (%) | 2 days ago40% | 2 days ago43% |
TrendMonth ODDS (%) | 2 days ago36% | 2 days ago44% |
Advances ODDS (%) | 10 days ago45% | 15 days ago62% |
Declines ODDS (%) | 3 days ago36% | 2 days ago45% |
BollingerBands ODDS (%) | 2 days ago46% | 2 days ago87% |
Aroon ODDS (%) | N/A | 2 days ago57% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
DBC | 22.78 | 0.23 | +1.02% |
Invesco DB Commodity Tracking | |||
BBIB | 100.11 | 0.08 | +0.08% |
JPMorgan BetaBuilders U.S.TrsBd3-10YrETF | |||
IAF | 4.62 | N/A | N/A |
abrdn Australia Equity Fund | |||
IAGG | 51.30 | -0.02 | -0.04% |
iShares Core International Aggt Bd ETF | |||
CVLC | 81.26 | -0.14 | -0.17% |
Calvert US Large-Cp Cor Rspnb ETF |
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
---|---|---|---|---|
BSX | 100% | -0.89% | ||
ISRG - BSX | 71% Closely correlated | +0.12% | ||
SYK - BSX | 67% Closely correlated | -0.13% | ||
MMSI - BSX | 56% Loosely correlated | -0.29% | ||
ALC - BSX | 49% Loosely correlated | +0.30% | ||
EW - BSX | 49% Loosely correlated | -1.26% | ||
More |